Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manabu Iwasaki

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Japanese Journal of Statistics and Data Science|November 21, 2022
Special feature: data science-present and futureManabu Iwasaki
Pharmaceutical Statistics|February 14, 2012
Sample size re-estimation for survival data in clinical trials with an adaptive designKanae Togo, Manabu Iwasaki
Journal of Biopharmaceutical Statistics|August 21, 2013
Optimal timing for interim analyses in clinical trialsKanae Togo, Manabu Iwasaki
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|May 15, 2007
Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous rHuEPO in Japanese dialysis patientsTadao Akizawa, Shozo Koshikawa, Manabu Iwasaki, et al.
Analytical Sciences : the International Journal of the Japan Society for Analytical Chemistry|February 11, 2010
A practical method for determining minimum detectable values in pulse-counting measurementsYoichiro Furukawa, Manabu Iwasaki, Akihiro Tanaka
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|May 7, 2015
High Hemoglobin Levels Maintained by an Erythropoiesis-Stimulating Agent Improve Renal Survival in Patients with Severe Renal ImpairmentYoshiharu Tsubakihara, Tadao Akizawa, Manabu Iwasaki, et al.
Advances in Therapy|April 7, 2019
Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled TrialTadao Akizawa, Manabu Iwasaki, Tetsuro Otsuka, et al.
Journal of the American Society of Nephrology : JASN|September 11, 2020
Authors' ReplyTadao Akizawa, Manabu Iwasaki, Yusuke Yamaguchi, et al.
Kidney International Reports|July 26, 2021
Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKDTadao Akizawa, Manabu Iwasaki, Tetsuro Otsuka, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|February 9, 2008
Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patientsMakoto Hiramatsu, Minoru Kubota, Manabu Iwasaki, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Japanese Journal of Statistics and Data Science|November 21, 2022
Special feature: data science-present and futureManabu Iwasaki
Pharmaceutical Statistics|February 14, 2012
Sample size re-estimation for survival data in clinical trials with an adaptive designKanae Togo, Manabu Iwasaki
Journal of Biopharmaceutical Statistics|August 21, 2013
Optimal timing for interim analyses in clinical trialsKanae Togo, Manabu Iwasaki
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|May 15, 2007
Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous rHuEPO in Japanese dialysis patientsTadao Akizawa, Shozo Koshikawa, Manabu Iwasaki, et al.
Analytical Sciences : the International Journal of the Japan Society for Analytical Chemistry|February 11, 2010
A practical method for determining minimum detectable values in pulse-counting measurementsYoichiro Furukawa, Manabu Iwasaki, Akihiro Tanaka
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|May 7, 2015
High Hemoglobin Levels Maintained by an Erythropoiesis-Stimulating Agent Improve Renal Survival in Patients with Severe Renal ImpairmentYoshiharu Tsubakihara, Tadao Akizawa, Manabu Iwasaki, et al.
Advances in Therapy|April 7, 2019
Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled TrialTadao Akizawa, Manabu Iwasaki, Tetsuro Otsuka, et al.
Journal of the American Society of Nephrology : JASN|September 11, 2020
Authors' ReplyTadao Akizawa, Manabu Iwasaki, Yusuke Yamaguchi, et al.
Kidney International Reports|July 26, 2021
Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKDTadao Akizawa, Manabu Iwasaki, Tetsuro Otsuka, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|February 9, 2008
Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patientsMakoto Hiramatsu, Minoru Kubota, Manabu Iwasaki, et al.
Pageof 4